EGFR and colorectal carcinoma: While therapies like pembrolizumab (NCT03991819, NCT01295827, and NCT02130466) have shown activity, the CRC shows decreasing susceptibility to monotherapies, owing to resistance mechanisms such as increased EGFR signaling (NCT03225664, NCT03299088).